Mediomics公司2001年成立，致力于为学术机构、制药公司、医学研究者、环境研究者提供创新性的检测试剂盒及生物感应物质。Mediomics拥有Patented Bridge-It® Assay Platform、Patented FRET-PINCER® Assay Platform、Patented TRF-PINCER® Assay Platform三大技术平台。

Mediomics, LLC provides innovative assay kits and biosensors needed by academic research laboratories, point of care testing, pharmaceutical companies, as well as medical and environmental research markets.  

Technology platforms:

（1）Patented Bridge-It® Assay Platform

Bridge-It® Assays are optimized to measure DNA binding proteins, their ligands, and co-regulators. Mediomics’ Bridge-It® assay was based on a simple idea of splitting the DNA binding site for a protein into two DNA half-sites. The presence of the DNA-binding protein or one of its ligands can be detected by FRET (fluorescence resonance energy transfer).

（2）Patented FRET-PINCER® Assay Platform

FRET-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected FRET-PINCER® Assay system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light through FRET (fluorescence resonance energy transfer).

（3）Patented TRF-PINCER® Assay Platform

TRF-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected TRF-PINCER® Assay platform system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light with Time-Resolved Fluorometry (TRF) sensitivity.

主要产品线包括：

（1）Bridge-It® Assay

（2）TR-FRET Bridge-It® Assay

（3）FRET-PINCER® Assay

（4）TR-FRET PINCER®Assay

（5）Other

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技代理Screenfect品牌全系列产品

ScreenFect GmbH成立于2012年，是一家专注于细胞转染技术创新的德国生物技术公司。ScreenFect®转染试剂是该公司的核心产品，是依托组合化学方法构建独特化学文库，通过高通量细胞筛选平台高效开发的转染试剂。ScreenFect®转染试剂适用于多种核酸分子（包括pDNA、siRNA、mRNA、miRNA）的单转染与共转染，在难转染细胞（如原代细胞、干细胞）中具有优异性能。

▎ScreenFect®转染试剂

● ScreenFect®A是一款通用型转染试剂，适用于pDNA、siRNA、mRNA的递送以及共转染实验，可广泛应用于多种细胞系（如HEK、HeLa、MEF）及部分原代细胞系。高效转染：在96孔板中仅需低于100ng DNA即可实现高转染效率。

● ScreenFect®siRN 是转染小干扰RNA双链体的理想选择，适用于HEK、HeLa、MEF等标准哺乳动物细胞系及多种原代细胞系。

● ScreenFect®mRNA是专为mRNA转染优化的高效试剂。

● ScreenFect®A-plus是一款多功能增强型转染试剂，适用于pDNA、siRNA、mRNA的转染及共转染实验，在几乎所有细胞系（包括难转染细胞）中均能实现高效转染。

ScreenFect®转染试剂具有以下特点：

● 低细胞毒性：显著降低对细胞活性的影响

● 省时一步法：支持细胞铺板与转染同步操作（即用型方案）

● 快速优化：针对新用户/新细胞系提供简易优化流程

● 血清兼容性：无需更换培养基，可直接在含血清环境下使用

● 无动物源成分：杜绝动物源性物质污染风险

● 高通量适用：完美适配大规模筛选实验需求

▎ScreenFect®UP-293

ScreenFect®UP-293 是一款专为高效生产抗体及蛋白设计的转染试剂，适用于HEK 293-F悬浮细胞体系。配合ScreenFect®Booster增效剂使用，可最大化提升悬浮细胞中的蛋白产量。

▎ScreenFect®Booster

在完成HEK293F悬浮细胞的ScreenFect®UP-293转染后，于转染后16小时添加ScreenFect®Booster增效剂，可显著提升蛋白产量。该增效剂含特定复合组分，通过重编程细胞代谢路径（从增殖模式转向蛋白合成模式），从而高效提升大多数目标蛋白的表达水平。

Buhlmann公司是一家瑞士公司，专注于胃肠病学、量子蓝、自身免疫性、细胞过敏、神经免疫学、临床化学、时间生物学、其他免疫分析相关产品的研发、生产、销售。

BÜHLMANN is a fully independent, medium sized and family owned Swiss company. The company was founded in 1976 and has continuously developed over the years. Sister companies have been established in Austria (BÜHLMANN in Austria GmbH) in 1996, in France (BÜHLMANN France SAS) in 2002, in Italy (BUHLMANN Italia srl) in 2009 and Brasil (BÜHLMANN Brasil) in 2013. Since 2005, BÜHLMANN products are directly distributed in Germany.

Buhlmann公司的主要产品包括：

Gastroenterology

Quantum Blue

Autoimmunity

Cellular Allergy

Neuroimmunology

Clinical Chemistry

Chronobiology

Special Products

Other Immunoassays